NCT07029399 - A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions

HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid TumorsHR+ HER2- Breast CancerOvarian CancerEndometrial CancerUterine Carcinosarcoma

Interventions

DRUG

NKT5097 CDK2/CDK4 dual degrader

NKT5097 will be distributed in tablet form and dosed daily or twice a day

Trial Locations (8)

22031

RECRUITING

NEXT Virginia, Fairfax

34232

RECRUITING

SCRI Florida Cancer Specialists - Sarasota, Sarasota

49546

RECRUITING

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

84119

RECRUITING

South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City

02115

RECRUITING

Dana-Farber Cancer Institute, Boston